{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:42:23Z","timestamp":1789771343087,"version":"4.0.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Blockade of interleukin-6 (IL-6) has emerged as a promising therapeutic option for antibody-mediated rejection. Subtherapeutic anti-IL-6 antibody level or treatment cessation following prolonged cytokine neutralization may result in proinflammatory rebound phenomena via accumulation of IL-6 and\/or modulated gene expression of major components of the IL-6\/IL-6 receptor (IL-6R) axis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We evaluated biologic material obtained from a randomized controlled, double-blind phase 2 trial designed to evaluate the safety and efficacy of the anti-IL-6 monoclonal antibody clazakizumab in late antibody-mediated rejection. Twenty kidney transplant recipients, allocated to clazakizumab or placebo, received 4-weekly doses over 12 wks, followed by a 40-wk extension where all recipients received clazakizumab. Serum proteins were detected using bead-based immunoassays and RNA transcripts using quantitative real-time polymerase chain reaction (peripheral blood) or microarray analysis (serial allograft biopsies).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Clazakizumab treatment resulted in a substantial increase in median total (bound and unbound to drug) serum IL-6 level (1.4, 8015, and 13 600 pg\/mL at 0, 12, and 52 wks), but median level of free (unbound to drug) IL-6 did not increase (3.0, 2.3, and 2.3 pg\/mL, respectively). Neutralization of IL-6 did not boost soluble IL-6R or leukocyte or allograft expression of IL-6, IL-6R, and glycoprotein 130 mRNA. Cessation of treatment at the end of the trial did not result in a meaningful increase in C-reactive protein or accelerated progression of graft dysfunction during 12 mo of follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion.<\/jats:title>\n            <jats:p>Our results argue against clinically relevant rebound phenomena and modulation of major components of the IL-6\/IL-6R axis following prolonged IL-6 neutralization with clazakizumab.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004285","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T12:06:29Z","timestamp":1660565189000},"page":"495-503","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena"],"prefix":"10.1097","volume":"107","author":[{"given":"Anita","family":"Borski","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farsad","family":"Eskandary","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Haindl","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Doberer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"M\u00fchlbacher","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip F.","family":"Halloran","sequence":"additional","affiliation":[{"name":"The Alberta Transplant Applied Genomics Centre, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chong","sequence":"additional","affiliation":[{"name":"Vitaeris Inc (acquired by CSL Behring, King of Prussia, PA, USA), Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wahrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0000000000003274","article-title":"Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation.","volume":"105","author":"Irish","year":"2021","journal-title":"Transplantation"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"e14337","DOI":"10.1111\/ctr.14337","article-title":"Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection\u2014the long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study.","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transplant"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The banff 2019 kidney meeting report (i): updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.kint.2021.11.029","article-title":"Allorecognition and the spectrum of kidney transplant rejection.","volume":"101","author":"Callemeyn","year":"2022","journal-title":"Kidney Int"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/tri.13436","article-title":"The therapeutic challenge of late antibody-mediated kidney allograft rejection.","volume":"32","author":"B\u00f6hmig","year":"2019","journal-title":"Transpl Int"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantion society working group.","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection.","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial.","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MOT.0000000000000832","article-title":"New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment.","volume":"26","author":"Mayer","year":"2021","journal-title":"Curr Opin Organ Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients.","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection.","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1097\/TP.0000000000003249","article-title":"Interleukin-6: an important mediator of allograft injury.","volume":"104","author":"Jordan","year":"2020","journal-title":"Transplantation"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease.","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"E3528","DOI":"10.3390\/ijms19113528","article-title":"The two-faced cytokine IL-6 in host defense and diseases.","volume":"19","author":"Narazaki","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","article-title":"The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo\/active-controlled, dose-ranging study.","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(17)30401-4","article-title":"Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.","volume":"389","author":"Aletaha","year":"2017","journal-title":"Lancet"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"e13908","DOI":"10.1111\/ctr.13908","article-title":"Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.","volume":"34","author":"Lavacca","year":"2020","journal-title":"Clin Transplant"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/TP.0000000000002895","article-title":"Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection.","volume":"104","author":"Shin","year":"2020","journal-title":"Transplantation"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6002\/ect.2020.0389","article-title":"Interleukin 6 receptor blockade to treat chronic active antibody-mediated rejection in kidney transplant: a case report with review of relevant literature.","volume":"20","author":"Sharma","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.3390\/jcm10194359","article-title":"Tocilizumab and desensitization in kidney transplant candidates: personal experience and literature review.","volume":"10","author":"Weinhard","year":"2021","journal-title":"J Clin Med"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease.","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer.","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann Oncol"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ajt.16709","article-title":"Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates.","volume":"22","author":"Jouve","year":"2022","journal-title":"Am J Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/eji.1830221110","article-title":"High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.","volume":"22","author":"Lu","year":"1992","journal-title":"Eur J Immunol"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13063-018-3158-6","article-title":"Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.","volume":"20","author":"Eskandary","year":"2019","journal-title":"Trials"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin Chem"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ajt.14600","article-title":"Review: the transcripts associated with organ allograft rejection.","volume":"18","author":"Halloran","year":"2018","journal-title":"Am J Transplant"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(92)81004-6","article-title":"The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand.","volume":"306","author":"Zohlnh\u00f6fer","year":"1992","journal-title":"FEBS Lett"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.intimp.2008.07.002","article-title":"Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production.","volume":"8","author":"Uchiyama","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-291X(88)81056-8","article-title":"The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes.","volume":"155","author":"Moshage","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0006-291X(88)80043-3","article-title":"Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines.","volume":"157","author":"Ganapathi","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ndt\/gfw027","article-title":"Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.","volume":"31","author":"Schwaiger","year":"2016","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:18:26Z","timestamp":1749061106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004285","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}